Trial · NCT07887126
Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis
NCT07887126, Not applicable, Not yet recruiting, The First Affiliated Hospital of Shihezi University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis. Trials, record NCT07887126. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07887126
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis
- NCT number
- NCT07887126
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 200 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Shihezi University
- Conditions
- Brucellosis
- Interventions
- Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical and microbiological composite cure rate at Week 6 (end of treatment) | 6 weeks after randomization (end of 6-week treatment) | Composite cure defined as resolution of clinical symptoms plus negative brucella culture / NGS test at the end of 6-week treatment. |
| Secondary | Recurrence rate at 24 weeks after end of treatment | 24 weeks post treatment completion | Proportion of participants with confirmed brucellosis recurrence 24 weeks after stopping 6-week therapy. |
| Secondary | Recurrence rate at 48 weeks after end of treatment | 48 weeks post treatment completion | Proportion of participants with confirmed brucellosis recurrence 48 weeks after stopping 6-week therapy. |
| Secondary | Change in quality of life assessed by SF-36 | Baseline, week 6, week 24, week 48 | Change in SF-36 health-related quality of life score from baseline to week 6, 24 and 48. |
| Secondary | Treatment adherence rate | 6-week treatment period | Proportion of participants with ≥90% medication adherence during the 6-week treatment course. |
| Secondary | Incidence of treatment-related adverse events | From treatment start through week 48 | Treatment-related adverse events graded per CTCAE, including hepatic injury, gastrointestinal reactions, hematological abnormalities and other adverse events. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07887126
GET https://conductscience.org/api/trials/v1/NCT07887126/registered